Latest Collagen News

Holista Colltech reported positive adjusted operating cash flow of A$318,000 for the September quarter, although statutory cash flow remained negative after its final ProImmune settlement payment. The company also pushed the planned start of its Collie collagen plant from December 2026 to May-July 2027, while ending the quarter with just A$23,000 in cash.

Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Holista Colltech's joint venture Ovicoll has acquired industrial land in Collie to build a modular sheep collagen production plant, aiming for operation by December 2026.

Holista Colltech has partnered with Swang Chai Chuan to develop a nano-collagen production facility in Western Australia, marking a major step in commercialising its collagen technology with a $1.6 million initial investment.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.